Annular rupture is an umbrella term covering different procedural-related injuries that may occur in the region of the aortic root and the left ventricular outflow tract during transcatheter aortic valve replacement. According to the anatomical location of the injury, there are 4 main types: supra-annular, intra-annular, subannular, and combined rupture. Treatment approaches include conventional cardiac procedure, isolated pericardial drainage, and conservative therapy. This summary describes theoretical and practical considerations of the etiology, pathophysiology, classification, natural history, diagnostic and treatment strategies, and prevention approaches of annular rupture. 5.7 to 8.3 years). At 7-year follow-up, PCI by sirolimus-eluting stents and MIDCAB in isolated proximal left anterior descending lesions yielded similar long-term outcomes regarding the primary composite clinical endpoint (22% PCI vs. 12% MIDCAB; p ¼ 0.17) and quality of life. Target vessel revascularization was more frequent in the PCI group (20% vs. 1.5%; p < 0.001).
The influence of access site on patient outcomes was studied in 439,947 procedures from the BCIS (British Cardiovascular Intervention Society) database. This study with a high proportion of transradial access (TRA) procedures (210, 260) observed an association with TRA and reduced bleeding and access site complications in stable, non-ST-segment elevation acute coronary syndrome (NSTEACS) and STEACS presentations. An association with reduced major adverse cardiac events was observed in NSTEACS and STEACS. The same associations were observed in a matched cohort comparing TRA to femoral access using closure devices. This suggests the effects observed in randomized trials translate into real patient benefits in routine practice. The indications of percutaneous edge-to-edge mitral valve repair with the MitraClip system are currently limited by strict echocardiographic criteria. Broadening indications for this therapy could potentially benefit a large number of patients that are referred to isolated medical management, likely carrying poor long-term prognosis. In the present study, patients that fulfilled the expanded echocardiographic criteria demonstrated similar safety at 30-day follow-up and efficacy through 12-month follow-up after MitraClip implantation compared with safety and efficacy in the control (i.e., strict criteria) group. Furthermore, both groups revealed statistically significant left ventricle reverse remodeling at 12 months, but the between-group baseline differences were sustained. patients after failed mitral bioprosthesis (n ¼ 6) and ring annuloplasty (n ¼ 11). All patients were in New York Heart Association class $III with a high surgical risk (Society of Thoracic Surgeons score 18 AE 22%). Procedure was successful in 14 patients (82%). The 18-month survival was 78 AE 14% for patients with elective procedure. At last follow-up, 75% of patients were in New York Heart Association class #II. Transfemoral transcatheter heart valve implantation for deterioration of mitral bioprosthesis or surgical repair provides encouraging immediate and midterm results and may be considered for patients unsuitable for surgery or at very high surgical risk. 
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